Hansa Biopharma AB (HNSA) NPV
0.14 SEK
(0.47%)
- Add to watchlist
- This stock can be held in a
0.14 SEK
(0.47%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
0.14 SEK
(0.47%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
Contact details
Important dates
General stock information
- Short code:
- HNSA
- ISIN:
- SE0002148817
- Market cap:
- 2.03 billion SEK
- Shares in issue:
- 67.81 million
- Sector:
- Biotechnology
- Exchange:
- Stockholm Stock Exchange
- Country:
- Sweden
- Currency:
- Swedish Krona
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.